Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$263.58+0.1%$237.54$187.62▼$267.47$465.02B0.35.72 million shs5.56 million shsIRWDIronwood Pharmaceuticals$3.56-6.3%$3.84$0.71▼$5.78$619.62M0.22.06 million shs1.25 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.03%+3.87%+3.83%+24.53%+37.79%IRWDIronwood Pharmaceuticals-6.32%-8.25%-17.21%-13.80%+300.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$263.58+0.1%$237.54$187.62▼$267.47$465.02B0.35.72 million shs5.56 million shsIRWDIronwood Pharmaceuticals$3.56-6.3%$3.84$0.71▼$5.78$619.62M0.22.06 million shs1.25 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.03%+3.87%+3.83%+24.53%+37.79%IRWDIronwood Pharmaceuticals-6.32%-8.25%-17.21%-13.80%+300.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$269.292.16% UpsideIRWDIronwood Pharmaceuticals 2.71Moderate Buy$6.2375.09% UpsideCurrent Analyst Ratings BreakdownLatest IRWD and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026ABBVAbbVie BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$275.00 ➝ $300.007/24/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)7/22/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$273.00 ➝ $282.007/15/2026ABBVAbbVie CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026ABBVAbbVie UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026ABBVAbbVie BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$258.00 ➝ $300.007/10/2026ABBVAbbVie Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $295.007/10/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$234.00 ➝ $276.007/10/2026ABBVAbbVie Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$260.00 ➝ $280.007/9/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$249.00 ➝ $261.007/9/2026ABBVAbbVie JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $280.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$62.82B7.41$15.17 per share17.38($1.83) per share-144.03IRWDIronwood Pharmaceuticals$296.15M1.96$0.24 per share14.76($1.61) per share-2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03129.8416.270.875.79%-576.45%13.39%7/31/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.605.93N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)Latest IRWD and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026IRWDIronwood Pharmaceuticals$0.32N/AN/AN/A$114.84 millionN/A7/31/2026Q2 2026ABBVAbbVie$3.60N/AN/AN/A$16.78 billionN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.63%+6.80%340.89%53 YearsIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALatest IRWD and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.732.83%7/15/20267/15/20268/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68IRWDIronwood PharmaceuticalsN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%IRWDIronwood Pharmaceuticals9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableIRWD and ABBV HeadlinesRecent News About These CompaniesTop profitable small caps trading at bargain P/E multiples during Q2 earningsJuly 27 at 11:33 AM | msn.comGlobeflex Capital L P Purchases New Shares in Ironwood Pharmaceuticals, Inc. $IRWDJuly 23, 2026 | marketbeat.comHere's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum StockJuly 15, 2026 | zacks.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.1% - What's Next?July 14, 2026 | marketbeat.comIronwood Pharmaceuticals Inc. Cl AJuly 14, 2026 | barrons.comIronwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting PatientsJuly 14, 2026 | businesswire.comIronwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The GapJuly 13, 2026 | seekingalpha.comInsider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Sells $578,062.80 in StockJuly 10, 2026 | insidertrades.comIronwood Pharmaceuticals (NASDAQ:IRWD) Insider Sells $578,062.80 in StockJuly 9, 2026 | marketbeat.com4 Defensive Stocks to Take Refuge in as Tech Sell-off ContinuesJuly 8, 2026 | zacks.comIronwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings MomentumJuly 3, 2026 | finance.yahoo.comIronwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings MomentumJuly 3, 2026 | insidermonkey.comZacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerJune 26, 2026 | zacks.com5 Small Drug Stocks to Invest in Amid a Biotech ComebackJune 25, 2026 | zacks.com10 small-cap US healthcare stocks with the strongest momentum gradesJune 24, 2026 | msn.comIronwood Pharma Shareholders Reaffirm Board and Governance StructureJune 18, 2026 | tipranks.comInsider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 21,571 Shares of StockJune 18, 2026 | insidertrades.comIronwood Pharma Strengthens Balance Sheet With Note RepaymentJune 15, 2026 | tipranks.comThese healthcare stocks are combining strong gains with reasonable pricesJune 12, 2026 | seekingalpha.comCan Linzess Continue Driving IRWD's Revenue Growth Through 2026?June 11, 2026 | zacks.comIronwood (IRWD) Q1 2026 Earnings Call TranscriptJune 2, 2026 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRWD and ABBV Company DescriptionsAbbVie NYSE:ABBV$263.58 +0.38 (+0.14%) Closing price 07/29/2026 03:59 PM EasternExtended Trading$263.30 -0.28 (-0.11%) As of 07/29/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Ironwood Pharmaceuticals NASDAQ:IRWD$3.56 -0.24 (-6.32%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$3.63 +0.07 (+1.97%) As of 07/29/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
